TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07610278: A Multicenter, Randomized, Double-blind, Factorial Design Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of HDY015 Administered as a Free Combination of QCZ484 and Inclisiran Compared to QCZ484,

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,847,200

Rescue Site Savings

+$3,187,200

Unlock Full NCT07610278 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07610278 Rescue Dossier →